Pietro G Lacaita, Andrea S Klauser, Julia Held, David Haschka, Gerlig Widmann, Gudrun M Feuchtner
{"title":"Association between coronary monosodium urate deposits at DECT and high-risk coronary plaque phenotypes and other features in gout patients.","authors":"Pietro G Lacaita, Andrea S Klauser, Julia Held, David Haschka, Gerlig Widmann, Gudrun M Feuchtner","doi":"10.1186/s41747-025-00611-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Dual-energy computed tomography (DECT) detects monosodium urate (MSU) deposits in joints. However, the correlation between coronary atherosclerosis phenotypes and MSU-positive lesions in the cardiovascular system remains unclear. We investigated the correlation between coronary MSU-positive plaques on unenhanced DECT with the coronary atherosclerosis profile at coronary CT angiography.</p><p><strong>Methods: </strong>One hundred fifty rheumatologic patients were prospectively enrolled. Sixty of them underwent unenhanced DECT and 128-row DECT coronary angiography. Analysis included CAD-RADS stenosis severity, high-risk plaque (HRP) phenotypes, and coronary artery calcium (CAC) score.</p><p><strong>Results: </strong>Of 60 patients, with a mean age of 63.7 years, including 7 females (11.7%), 37 had gout (61.7%), 9 had hyperuricemia (15%), and 14 had other rheumatologic diseases (23.3%). At DECT, 11 (18.3%) had coronary MSU-positive lesions totaling 24 lesions (left anterior descending, 12; right coronary artery, 10; circumflex, 1; left main, 1). HRP phenotypes were identified in 14 of 60 patients (23.3%). The prevalence of HRP was higher in MSU-positive than MSU-negative patients (63.3% versus 14.2%; p = 0.003; odds ratio 9.91; 95% confidence interval [CI]: 2.30-48.41). CAD-RADS and CAC scores correlated with the number of MSU-positive lesions (ρ = 0.412; 95% CI: 0.167-0.609; p < 0.001) and ρ = 0.412; 95% CI: 0.169-0.609; p < 0.001). None of the major cardiovascular risk factors (smoking, hypertension, dyslipidemia, or diabetes) was associated with MSU-positive lesions.</p><p><strong>Conclusion: </strong>We found an association between coronary MSU-positive lesions and HRP-phenotypes, as well as a correlation with stenosis severity and calcium burden. MSU-positive lesions may serve as an unenhanced DECT-derived biomarker of increased cardiovascular risk.</p><p><strong>Relevance statement: </strong>The detection of coronary MSU-positive lesions by DECT could indicate an increased likelihood of HRP phenotypes. These findings suggest their potential as imaging biomarkers for cardiovascular risk, using unenhanced spectral DECT scans or photon-counting CT.</p><p><strong>Key points: </strong>Identifying gout patients with increased cardiovascular risk remains challenging. Coronary MSU-positive lesions detected on unenhanced DECT may be associated with HRP features on coronary computed tomography angiography. MSU-positive lesions could serve as biomarkers for cardiovascular risk in gout patients.</p>","PeriodicalId":36926,"journal":{"name":"European Radiology Experimental","volume":"9 1","pages":"73"},"PeriodicalIF":3.6000,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12339842/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology Experimental","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/s41747-025-00611-z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Dual-energy computed tomography (DECT) detects monosodium urate (MSU) deposits in joints. However, the correlation between coronary atherosclerosis phenotypes and MSU-positive lesions in the cardiovascular system remains unclear. We investigated the correlation between coronary MSU-positive plaques on unenhanced DECT with the coronary atherosclerosis profile at coronary CT angiography.
Methods: One hundred fifty rheumatologic patients were prospectively enrolled. Sixty of them underwent unenhanced DECT and 128-row DECT coronary angiography. Analysis included CAD-RADS stenosis severity, high-risk plaque (HRP) phenotypes, and coronary artery calcium (CAC) score.
Results: Of 60 patients, with a mean age of 63.7 years, including 7 females (11.7%), 37 had gout (61.7%), 9 had hyperuricemia (15%), and 14 had other rheumatologic diseases (23.3%). At DECT, 11 (18.3%) had coronary MSU-positive lesions totaling 24 lesions (left anterior descending, 12; right coronary artery, 10; circumflex, 1; left main, 1). HRP phenotypes were identified in 14 of 60 patients (23.3%). The prevalence of HRP was higher in MSU-positive than MSU-negative patients (63.3% versus 14.2%; p = 0.003; odds ratio 9.91; 95% confidence interval [CI]: 2.30-48.41). CAD-RADS and CAC scores correlated with the number of MSU-positive lesions (ρ = 0.412; 95% CI: 0.167-0.609; p < 0.001) and ρ = 0.412; 95% CI: 0.169-0.609; p < 0.001). None of the major cardiovascular risk factors (smoking, hypertension, dyslipidemia, or diabetes) was associated with MSU-positive lesions.
Conclusion: We found an association between coronary MSU-positive lesions and HRP-phenotypes, as well as a correlation with stenosis severity and calcium burden. MSU-positive lesions may serve as an unenhanced DECT-derived biomarker of increased cardiovascular risk.
Relevance statement: The detection of coronary MSU-positive lesions by DECT could indicate an increased likelihood of HRP phenotypes. These findings suggest their potential as imaging biomarkers for cardiovascular risk, using unenhanced spectral DECT scans or photon-counting CT.
Key points: Identifying gout patients with increased cardiovascular risk remains challenging. Coronary MSU-positive lesions detected on unenhanced DECT may be associated with HRP features on coronary computed tomography angiography. MSU-positive lesions could serve as biomarkers for cardiovascular risk in gout patients.